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Abstract
Previously, we showed three differentially sulfated forms of chondroitin sulfate proteoglycans (CSPG) associated with senile
plaques, astrocytes and neurofibrillary tangles in Alzheimer's disease. Here, monoclonal antibodies were used to demonstrate
CSPGs in other neurodegenerative diseases. CSPGs were found associated with inclusions of Parkinson's, diffuse Lewy body,
Pick's diseases, and progressive supranuclear palsy. Reacting astrocytes in each of these neurodegenrative diseases and
Huntington's disease showed immunoreactivity for CSPG. CSPG distribution in a variety of neurodegenerative diseases suggests
that similar mechanisms may be involved in the accumulation of proteoglycans in a number of filamentous inclusions.
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Parkinson's disease

Several neurological conditions are characterized by
intraneuronal, filamentous inclusions. The neuronal inclusions of Alzheimer's, Parkinson's, Pick's, diffuse
Lewy body (DLB) diseases, and progressive supranuclear palsy (PSP), are principally composed of cytoskeletal components and share many common epitopes [6-10,18,20,22]. The clinical manifestations of
the diseases, neuronal populations affected, and the
morphology of each inclusion are distinct. It is not
known whether similar, fundamental processes are involved in the formation of neuronal inclusions, or if
different types of inclusions arise through separate
mechanisms.
Certain proteoglycans have been associated with
different diseases. Proteoglycans are highly anionic
macromolecules that are usually found associated with
the extracellular matrix [13-15,31] where they have
been shown to play roles in cell adhesion and proliferation. Proteoglycans consist of a core protein with one
or more glycosaminoglycan side chains typically attached to a serine residue. Proteoglycans vary in the
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composition of the core protein, the number and type
of glycosaminoglycan chains and sulfate content. Heparan sulfate proteoglycans (HSPG) are found in systemic amyloidoses [12] as well as in the senile plaques
and neurofibrillary tangles (NFTs) of Alzheimer's disease and Down's syndrome [19,24,25,26]' Previously,
we found HSPG by demonstrating heparinase-sensitive
bFGF binding sites in the inclusions of several neurodegenerative diseases, including Pick's and Parkinson's diseases and PSP. However, diffuse Lewy bodies
lacked bFGF-binding sites. [17]
Chondroitin sulfate proteoglycans (CSPGs) can inhibit neurite outgrowth in vivo and in vitro [2,27].
CSPGs accumulate at injury sites in the central nervous system [1,16,21]' During injury to the CNS, C-6S
CSPG is associated with reacting astrocytes and is
particularly inhibitory to neurite outgrowth [16].
Whether astrocytes produce a specific proteoglycan
core protein during injury, or simply alter the usual
sulfation pattern is unknown.
Since CSPGs containing all three sulfation states of
chondroitin were shown to be associated with senile
plaques and NFTs of Alzheimer's disease [5], it seemed
likely, as in the case of HSPG, that CSPGs might also
be present in inclusions of other neurodegenerative
diseases. In this immunocytochemical study, we
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Fig. 1. Chondroitin sulfate immunoreactivity in Lewy bodies of
Parkinson's disease. Substantia nigra neuron containing multiple
Lewy bodies positive for (C-4S; panel A, arrowheads). Note typical
rim-like staining. Lewy bodies were also seen with a homogeneous,
pale staining (C-6S; panel S, arrowhead). !3ar = 25 p.m.

demonstrate CSPG in a variety of inclusions and reacting astrocytes associated with neurodegenerative diseases. Our study suggests that the inclusion-related
cytoskeletal changes may be part of a larger program of
structural reorganization which includes proteoglycans.
Tissue sections from the brains tern of 5 cases of
Parkinson's disease (ages 53-70) and from the frontal

or temporal cortex of 4 cases of OLB disease (ages
75-95) were examined for the presence of CSPG in
Lewy bodies. In addition, the pons of 4 cases of PSP
(ages 59-83), and frontal and temporal cortex of 2
cases of Pick's disease (ages 62, 68) were examined for
the association of CSPG with these other neuronal
inclusions. The caudate and putamen were examined
from 2 cases of Huntington's chorea (ages 57, 61). Five
control cases were also examined (57-83). All tissue
was fixed in buffered formalin and embedded in paraffin prior to sectioning at 6 ,urn.
lmmunostaining was performed by the peroxidase
anti-peroxidase method with 3'3'diaminobenzidine as
the co-substrate [29]. To detect CSPGs, three monoclonal antibodies each raised to different sulfation
states of chondroitin were used [4]. The three antibodies recognize the stubs of chondroitin 6-sulfate, chondroitin 4-sulfate, or unsulfated chondroitin, respectively, after chondroitinase digestion. Tissue sections
were incubated with chondroitinase ABC [30] (Sigma)
at 1 U jml in Tris-acetate buffer (pH 8) for 2 h at 37°C
or overnight at 20°C followed by overnight incubation
at 4°C with antibody. Omission of the chondroitinase
enzyme, substitution with heparinase and heparitinase
[17] treatments, or omission of the primary antibody
were used as controls. Antisera to T or ubiquitin were
used in adjacent sections to aid in identification of the
inclusions. Antisera to glial fibrilary acidic protein
(GFAP) was used to identify astrocytes.
The distribution of CSPGs in the different neurodegenerative diseases is summarized in Table 1. Lewy
bodies of Parkinson's disease found in pigmented neurons of the substantia nigra were immunostained for
unsulfated chondroitin (C-OS), chondroitin 4-sulfate
(C-4S) and chondroitin 6-sulfate (C-6S). Most Lewy
bodies had rim-like staining with less intense staining
of the core (Fig. lA). Some Lewy bodies were stained
uniformly and appeared more pale (Fig. IB).
lntraneuronal Pick bodies showed immunoreactivity
for C-OS and C-6S, whereas C-4S immunoreactivity was
confined to the cytoplasm surrounding Pick bodies
(Fig. 2A). C-OS immunoreactivity was substantially
weaker than C-6S and may indicate less of the unsulfated antigen.

Table I
Chondroitin sulfate proteoglycans are found in the disease specific inclusions of a variety of neurodegenerative diseases
Disorder

Structure

C-OS

C-4S

C-6S

Alzheimer's disease
Progressive supranuclear palsy
Pick's disease
Parkinson's disease
Diffuse Lewy body disease

Senile plaques and NITs
NITs
Pick bodies
Lewy bodies
Lewy bodies

+
+
+
+
+

+
+

+
+

+*
+
+

+
+
+

Unsulfated chondroitin (C-OS), chondroitin 4-sulfate proteoglycan (C-4S) and chondroitin 6-sulfate (C-6S) are found as indicated.

* The Pick body itself was unreactive for C-4, however, the cytoplasm surrounding the Pick body was positive. Chondroitin 4-sulfate is associated
with but not in the Pick body.
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Lewy bodies of DLB disease, which also have a
cortical distribution, contained all three forms of chondroitin. These inclusions were identified as intracellular and juxtanuclear (Fig. 2B). The DLB disease inclusions had a reticular staining pattern. Interestingly,
some DLBD inclusions were seen that lacked CSPG
immunoreactivity, others were somewhat immunoreactive, while many were intensely immunoreactive. This
pattern was the same for all three forms of CSPG.
Progressive supranuclear palsy was also examined.
NFTs of PSP also contained C-OS, C-4S, and C-6S.
Many large neurons contained CSPG apparently associated with fibrils inside the cell (Fig. 2C). C-OS immunoreactivity was substantially weaker than C-4S and
C-6S, which may indicate fewer unsulfated glycosaminoglycan chains per proteoglycan core protein.
Astrocytic reaction could be found in each of the
cases examined. These astrocytes showed C-4S and
C-6S immunoreactivity. Of the cases examined, the
Pick's cases showed the most extensive gliosis, as confirmed with antisera to GFAP. The Pick's cases also
had the most intense and greatest number of CSPGpositive astrocytes (Fig. 3A). The cases of DLB disease
had the least number of CSPG-positive, reacting astrocytes. In Parkinson's disease and PSP (Fig. 3B) the
CSPG-positive astrocytes were seen among inclusionbearing neurons. In the caudate and putamen of Huntington's disease, astrocytes positive for CSPG immunoreactivity were found (Fig. 3C) while the cortex of
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these cases showed relatively few. In controls, only a
small number of GFAP-positive astrocytes displayed
CSPG immunoreactivity.
In all cases, chondroitinase digestion was required
for antibody binding [4,5]. Antibody specificity was
demonstrated by a lack of immunoreactivity following
heparinase and heparitinase digestion or if chondroitinase treatment was absent.
In this study we demonstrated CSPGs associated
with intraneuronal inclusions of several neurodegenerative diseases. Inclusions of Pick's, DLB, and Parkinson's diseases, and from PSP are associated with all
three sulfation states of chondroitin. In addition, astrocytes contain C-4S and C-6S in these diseases as well
as Huntington's disease. Huntington's disease cases
were examined because this disease is characterized by
astrogliosis and neuronal loss but a lack of inclusions.
In a previous study, we demonstrated that glial cells
accumulate and secrete CSPGs in response to A{3 as a
substrate [3]. In this study, we found CSPG associated
with astrocytes in neurodegenerative diseases not characterized by A{3 deposits. Therefore, while A{3 may
play a key role in CSPG deposition around senile
plaques in Alzheimer's disease, it is unlikely to be the
sole initiator for CSPG accumulation in neurodegenerative diseases.
Extracellular proteoglycans have been shown to play
roles in cell proliferation, migration, and cell adhesion.
HSPGs and CSPGs are found primarily in the extracel-

Fig. 2. Pick bodies usually showed weak immunoreactivity for chondroitin (arrowheads), however, the cytoplasm surrounding the Pick body was
more intensely stained (C-4S; panel A, small arrowheads). Chondroitin immunoreactivity in diffuse Lewy bodies had a reticular staining pattern
(C-4S; panel B, arrowhead). NFTs in progressive supranuclear palsy showed chondroitin immunoreactivity associated with fibrils within the
cytoplasm (C-6S; panel C, arrowhead). Bar = 25 JLm.
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cessive internal accumulation of proteoglycans could
hinder normal intracellular transport, potentially inducing accumulation of many other proteins.
Proteoglycans may play an active role in the formation of these inclusions. Since the inclusions are comprised cytoskeletal components, one possibility is that
the cytoskeletal proteins are interacting with the proteoglycans to form the inclusion. These inclusions are
resistant to proteases. Proteoglycans have been shown
to alter normal proteolytic degradation of proteins
such as bFGF [23] and Af3 [11]. In addition, systemic
amyloidoses, which contain proteoglycans, are resistant
to proteolysis. The accumulation of proteoglycans in
the presence of abnormal cytoskeletal components
could prevent the efficient degradation and removal of
those abnormal fibrils, allowing them to persist. While
different types of inclusions occur in distinct neuronal
populations and consist of various proteins, proteoglycans appear to be a common component. Proteoglycan
protection from proteolysis could be a fundamental
mechanism leading to inclusion formation.
This work was supported by AG 07552 and AG
09287.

Fig. 3. Reacting astrocytes show CSPG immunoreactivity. Astrocytes
in gliosis of Pick's disease (C-6S; panel A). Some reactive astrocytes
are seen in close proximity to neurons with inclusions. An astrocyte
(small arrow) is located next to a PSP NFT (C-6S; panel B, large
arrow). Astrocytes in the caudate of a Huntington's patient (C-6S;
panel C). Bar = 20 /Lm.

lular matrix, but have been found intracellularly
[15,19,28]. HSPG and now CSPG have been shown to
be a common component of neuronal inclusions. Ex-
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